Published in Medical Letter on the CDC and FDA, March 13th, 2005
The briefing document, describing nearly 30 years of safe use of naproxen at both prescription and over-the-counter (OTC) dosages, was submitted in advance of the FDA's Arthritis and Drug Safety Advisory Committee Meeting. Bayer's naproxen sodium formulation has been sold as an OTC product under the trade name Aleve since 1994.
Bayer believes that its confidence in Aleve is well supported by the data in the briefing document and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.